NGM raises $13M for cardio/metabolic R&D work

NGM Biopharmaceuticals has raised a little more than $13 million of a planned $50 million round, according to the San Francisco Business Times. The company, which includes Genentech legend Art Levinson on its board, has been engaged in basic scientific research for the past 5 years, with a special focus on cardio/metabolic work. One of its projects includes work on finding the genes turned on and off by gastric bypass surgery, which is known to eliminate symptoms of the disease even ahead of weight loss. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.